ARK Invest's position in CMPS, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| ARKG | 5,863,409 | $53.5M | 2.71% | #15 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-03 | ARKG | Buy | Added | 600,709 | $5.2M |
| 2026-10-12 | ARKG | Buy | Added | 284,019 | $3.3M |
| 2026-10-09 | ARKG | Buy | Added | 7,700 | $92K |
| 2026-07-24 | ARKG | Buy | Added | 107,121 | $1.2M |
| 2026-07-23 | ARKG | Buy | Added | 31,016 | $363K |
| 2026-07-22 | ARKG | Buy | Added | 42,091 | $502K |
| 2026-07-20 | ARKG | Buy | Added | 238,048 | $2.8M |
| 2026-07-17 | ARKG | Buy | Added | 101,791 | $1.3M |
| 2026-07-16 | ARKG | Buy | Added | 395,987 | $4.9M |
| 2026-07-15 | ARKG | Buy | Added | 7,929 | $106K |
| 2026-07-13 | ARKG | Buy | Added | 11,875 | $157K |
| 2026-07-10 | ARKG | Buy | Added | 37,822 | $516K |
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx…
See CMPS's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open CMPS on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.